Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolic Complications Clear all

Conditions: Type I Diabetes Mellitus Without Complication, Eating Disorder
Interventions: Not listed
Lead sponsor: HealthPartners Institute; Other
Eligibility: 14 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Intellectual Disability, Neurodevelopmental Disorders, Autism Spectrum Disorder, Down Syndrome, Fragile X Syndrome, Cri-du-Chat Syndrome, De Lange Syndrome, Mental Retardation, X-Linked, Prader-Willi Syndrome, Rubinstein-Taybi Syndrome, Trisomy 13 Syndrome, WAGR Syndrome, Williams Syndrome
Interventions: PACE Program; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Chapel Hill, North Carolina

Conditions: Hypoglycemia, Infant, Small for Gestational Age, Premature Birth of Newborn, Fetal Macrosomia, Intrauterine Growth Restriction, Complication of Prematurity, Neonatal Hypoglycemia
Interventions: 40% Dextrose gel; Dietary Supplement
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 0 Hours to 1 Hour
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetic Neuropathies
Interventions: CBD; Drug
Lead sponsor: Pure Green; Industry
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Sterling Heights, Michigan

Conditions: End Stage Renal Disease, Renal Impairment, Obesity, Overweight
Interventions: Ribupatide; Drug
Lead sponsor: Kailera; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Conditions: Hypocalcemia, Pseudohypoparathyroidism, Osteomalacia, Rickets, Pseudopseudohpoparathyroidism
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Months to 100 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes, Hypertension, Diabetic Kidney Disease
Interventions: Pharmacist telehealth intervention; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Gestational Diabetes
Interventions: Education; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Foot Ulcer, Diabetic
Interventions: NEOX® CORD 1K, Standard of Care (Pressure Bandage); Other · Procedure
Lead sponsor: Amniox Medical, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Tucson, Arizona • Castro Valley, California • Newnan, Georgia

Conditions: Endocrine Disease, Adrenal Insufficiency, Congenital Adrenal Hyperplasia
Interventions: Hydrocortisone Modified Release Capsules; Drug
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Hyperoxaluria
Interventions: Genetic Analysis; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 1 Day and older
Enrollment: 1,235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity, Pregnancy
Interventions: Dietary and lifestyle counseling; Behavioral
Lead sponsor: Carolinas Medical Center; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Fabry Disease
Interventions: migalastat HCl 150 mg; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia • Cleveland, Ohio • Fairfax, Virginia

Conditions: Type 2 Diabetes Mellitus
Interventions: Aliskiren, Irbesartan, Captopril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Respiratory Complication, Morbid Obesity
Interventions: Accelomyography, Neostigmine, Qualitative Monitor; Device · Drug
Lead sponsor: Coastal Anesthesiology Consultants; Other
Eligibility: Not listed
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Saint Augustine, Florida

Conditions: Obesity Associated With Defects in Leptin-melanocortin Pathway
Interventions: Setmelanotide; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Scottsdale, Arizona • San Diego, California • Gainesville, Florida + 10 more

Conditions: Distal Renal Tubular Acidosis
Interventions: ADV7103, Placebo; Drug
Lead sponsor: Advicenne Pharma; Industry
Eligibility: 6 Months to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 6
States / cities: Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 3 more

Conditions: Phenylketonuria, Maternal
Interventions: Pegvaliase; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: Female only
Enrollment: 50 participants
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Diabetes Mellitus
Interventions: Diabetes Mobile Application; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 14 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes in Pregnancy, Gestational Diabetes
Interventions: Insulin glargine alone, Insulin glargine + insulin lispro; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: New Brunswick, New Jersey • New York, New York

Conditions: Type 1 Diabetes Mellitus, Pregnancy in Diabetics
Interventions: Dexcom G6 CGM; Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Santa Barbara, California • Rochester, Minnesota • New York, New York

Conditions: Pregnancy Related, Weight Gain, Maternal
Interventions: Meal Delivery; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Feeding Disorder, Nutrition Disorder, Infant,Premature
Interventions: Metclopramide, Erythromycin, placebo; Drug
Lead sponsor: East Tennessee State University; Other
Eligibility: Up to 14 Days
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Johnson City, Tennessee

Conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
Interventions: Iron isomaltoside/ferric derisomaltose, Iron sucrose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 141
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Chula Vista, California + 96 more

Search by objective public record fields.

Type 1 Diabetes and Eating Disorder Diurnal Glucose Patterns

Physical Activity and Community EmPOWERment Project

Dextrose Gel Does Not Prevent Neonatal Hypoglycemia

The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy

A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide

Studies of States With Resistance to Vitamin D and Parathyroid Hormone

Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)

Gestation Diabetes N'Teractive Media-based Education (GDnME)

NEOX® CORD 1K vs Standard of Care in Non-healing Diabetic Foot Ulcers

Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH

Primary Hyperoxaluria Mutation Genotyping/Phenotyping

Does Dietary and Lifestyle Counseling Prevent Excessive Weight Gain During Pregnancy? A Randomized Controlled Trial

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?

Open-Label Extension Study of Setmelanotide

Study Evaluating Subjects With Distal Renal Tubular Acidosis

A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding

Mobile Application to Enhance Diabetic Care

Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)

Longitudinal Observation of Insulin Requirements and Sensor Use in Pregnancy

Healthier At-home Meals for Expectant Mothers

Use of Prokinetics in Early Enteral Feeding in Preterm Infants

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease